Rigel Pharmaceuticals
RIGL
163 hedge funds and large institutions have $401M invested in Rigel Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 50 increasing their positions, 56 reducing their positions, and 16 closing their positions.
80% more call options, than puts
Call options by funds: $1.35M | Put options by funds: $750K
13% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 16
10% more capital invested
Capital invested by funds: $365M → $401M (+$35.7M)
1% more funds holding
Funds holding: 162 → 163 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.19% less ownership
Funds ownership: 8.07% → 7.88% (-0.19%)
11% less repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 56
Top Buyers
| 1 |
Citadel Advisors
Miami,
Florida
|
+$6.91M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$4.89M |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
+$4.6M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
+$2.23M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$2.04M |
Top Sellers
| 1 |
Millennium Management
New York
|
-$5.54M |
| 2 |
TA
Tamarack Advisers
Carlsbad,
California
|
-$3.38M |
| 3 |
Goldman Sachs
New York
|
-$3.13M |
| 4 |
HP
HealthInvest Partners
Stockholm,
Sweden
|
-$2.89M |
| 5 |
State Street
Boston,
Massachusetts
|
-$2.82M |
RIGL Hedge Fund Activity: Q1 2022 in Review
163 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q1 2022, worth a combined $401M — up 9.8% from $365M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new RIGL positions and 16 closed out — a net gain of 2 holders — while 50 added to existing stakes and 56 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $6.91M. The largest seller was Millennium Management, cutting an estimated $5.54M.
- 163 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q1 2022, up from 162 in Q4 2021.
- Funds reported $401M of Rigel Pharmaceuticals stock for Q1 2022, up 9.8% quarter-over-quarter.
- 18 funds opened new Rigel Pharmaceuticals positions in Q1 2022 and 16 closed out, a net change of +2 holders.
- The largest Rigel Pharmaceuticals buyer in Q1 2022 was Citadel Advisors, an estimated $6.91M added.
- The largest Rigel Pharmaceuticals seller in Q1 2022 was Millennium Management, an estimated $5.54M sold.
Based on aggregated 13F filings for Q1 2022.